About PharmaEssentia PharmaEssentia Corporation is a global biopharmaceutical company with a pioneering spirit and a deep commitment to patients with rare and underserved diseases.

Our lead product, BESREMi® (ropeginterferon alfa-2b), is the first FDA-approved monotherapy for polycythemia vera (PV) regardless of treatment history, and we are actively advancing our clinical and real-world evidence programs across myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF).

Our pipeline includes landmark studies such as EXCEED-ET and HOPE-PMF, alongside a growing portfolio of investigator-initiated trials (IITs) and real-world evidence initiatives.

The Opportunity We are seeking a Scientist, Global Medical to serve as a key driver of our evidence generation strategy.

This role sits at the intersection of clinical research, investigator-initiated trials, and scientific publication—translating me...